close
Add to watchlist
Somaxon Pharmaceuticals Inc (SOMX) Healthcare
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. The company has completed four Phase III clinical trials for its lead product candidate, Silenor (doxepin hydrochloride) for the treatment of insomnia. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.57 |
| Volume | 52865 |
| Volume Avg | 219336 |
| 52 Week High | 3.07 |
| 52 Week Low | 0.42 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -1.27 |
| EPS change Q/Q | -13.51% |
| EPS change Q/Q Yr ago | -425% |
| EPS change Q/Q next Q est | -600% |
| EPS change Y/Y | -33.33% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | -0.06 |
| EPS next Y est | -0.07 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |